Estimates released by global investment giant Goldman Sachs project India will be the world's fifth-largest market for pharmaceuticals by 2020. According to the analysis, companies who have already established themselves in Indian will see the biggest returns as a result of this growth. Sun Pharmaceuticals and Nicholas Piramal were cited as two drug-makers with the best prospects to mine India's soon-to-be booming market. In fact, Nicolas Piramal has recently upped its sales force in the country to 3,300 and its pipeline now covers nine therapies. Another corporation looking to cash-in on India's future drug market is Glenmark. The company already boasts an extensive drug portfolio as well as a sales team with 1,900 representatives. Goldman Sachs said the steep increase in drug sales would come as a result of the country's high rates of urbanization and the proliferation of chronic "lifestyle" diseases. (Click here for more
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.
The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.
The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.
